Metronidazole Zentiva Pharma

Metronidazole, the active ingredient in Metronidazole Zentiva Pharma, is a nitroimidazole antibiotic presented as an oral dosage form for systemic use. It treats infections caused by susceptible anaerobic bacteria and certain protozoa in adults and children as prescribed by a healthcare professional.

GNH USA supplies Metronidazole Zentiva Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable logistics for timely delivery across global markets.

Metronidazole is used to treat infections caused by anaerobic bacteria and certain protozoa. - Bacterial vaginosis: eradicates the anaerobic bacterial overgrowth responsible for the condition. - Trichomoniasis: eliminates Trichomonas vaginalis, relieving symptoms and preventing recurrence. - Amoebiasis: clears intestinal Entamoeba histolytica infection and associated dysentery. - Intra‑abdominal and pelvic anaerobic infections: provides antibacterial coverage for mixed anaerobic flora. - Clostridioides difficile‑associated diarrhea (adjunct therapy): reduces toxin‑producing bacterial load when used with standard therapy.

Metronidazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset. - Metallic taste: transient metallic sensation. - Diarrhea: loose stools. - Headache: mild headache.

Serious or Rare Side Effects: - Seizures: rare neurologic events. - Peripheral neuropathy: tingling or numbness in extremities. - Severe allergic reactions: rash, swelling, or anaphylaxis.

Before prescribing Metronidazole, clinicians should consider several precautionary measures to ensure safe use. - Pregnancy: Category B, use only if benefits outweigh potential risks. - Alcohol consumption: avoid during therapy and for at least 48 hours after to prevent disulfiram‑like reaction. - Liver disease: dose adjustment may be required; monitor hepatic function. - Renal impairment: consider dose reduction in severe renal dysfunction. - Neurologic symptoms: discontinue if seizures or peripheral neuropathy develop. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Metronidazole can interact with several medicines, altering efficacy or increasing toxicity.

Major Interactions (Avoid): - Alcohol: concurrent use may cause severe flushing, tachycardia, and nausea. - Warfarin: may enhance anticoagulant effect, increasing bleeding risk. - Lithium: can raise lithium levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - Cimetidine: may increase metronidazole plasma concentrations. - Phenytoin: may reduce metronidazole levels, decreasing effectiveness. - Oral contraceptives: may reduce hormonal efficacy; advise additional contraceptive measures.